Atopic Dermatitis (AD) is also known as eczema. It’s a condition that makes the skin red and itchy, most common in children but can occur at any age. Atopic dermatitis is chronic and tends to flare periodically.
Sometimes it can be accompanied by asthma or hay fever. Currently, there is no cure for atopic dermatitis. Research has focused its efforts on finding relief solutions, but also treatments.
If you’re interested in how the whole therapeutic area of Dermatology is doing in Q1 of 2021 and how Covid-19 affected it and other TAs, check our 2021 Market Overview. We update it quarterly as new data becomes available so stay tuned for our next updates as well.
According to Medscape, the prevalence rate of Atopic Dermatitis is rising, and AD affects 15-30% of children and 2-10% of adults. This figure estimates the prevalence in developed countries.
In China and Iran, the prevalence rate is approximately 2-3%. The frequency is increased in patients who immigrate to developed countries from underdeveloped countries.
This map represents the prevalence in different countries:
If you want to see the top 5 countries with the highest prevalence as well as the top 5 with the highest incidence rate you can download the Full Feasibility Report for Atopic Dermatitis. It also includes Recruitment Rates and Trial Performance Statistics as well as Sites and Investigators.
Countries with past experience in clinical research in Atopic Dermatitis
The way we usually measure the research experience of a given country is by calculating the number of trials being performed for a million people. The map below shows on a global level which countries had more clinical trials than others compared to their population:
There are in total 566 completed clinical trials targeting patients with Atopic Dermatitis. 126 of them were completed in the last 3 years. The majority of all trials are pediatric clinical trials (286), as well as treatment as a purpose (354).
The countries with the most completed trials are the USA, Germany, and Canada, the United Kingdom, and Japan. Where the United States has almost 5 times more sites with experience than Germany.
If we look at the number of trials completed divided by the number of people who live there, then the ranking of countries looks different. Here are the top 5:
Latvia has a total of 7 clinical trials completed and we have identified 6 experienced in Atopic Dermatitis sites. Almost all clinical trials completed are in Phase 3.
Countries with active or recruiting clinical trials
As previously mentioned, research in Atopic Dermatitis has been increasing due to the higher number of patients in developed countries and lack of effective treatment.
At the moment there are 517 active, recruiting, or not yet recruiting clinical trials in the indication and most of them are in Phase 3. 121 of these studies are focused on treatment as a purpose.
The countries with the highest number of trials are the USA, Germany, the UK, and Japan. Though, if we want to measure the competition level when it comes to patient recruitment, it’s best to measure trials versus population.
Based on trials per million people the top countries with the highest competition are as follows:
On this map you can also get a better idea of the global competition in running clinical trials in Atopic Dermatitis:
Even though Estonia is the country with the most clinical trials per million people, it only has 2 really big centers (Talin and Tartu) where this research happens, leaving other regions available:
At the moment there are 17 active or recruiting clinical trials. Almost all are in Phase 3 and just a few are in Phase 2 but there are no trials in Phase 1.
The largest clinical trial including Estonia is looking to recruit 2678 patients. Interestingly enough the completed trials in Estonia are just 3, making it a relatively new destination for conducting research in this indication.
Do you need more data for Atopic Dermatitis? Download the Full Feasibility Report for a more in-depth analysis of the clinical research landscape.
TrialHub is a feasibility intelligence platform that supports feasibility, startup, patient recruitment and clinical project managers with a 360-degree overview of the clinical research landscape in order to plan successful and on-time clinical trials.
TrialHub does this by aggregating thousands of data sources in real-time and combining them with local experts’ insights.
The data provided in this article is gathered in November 2020 and is based on 17 clinical trial registries (clinicaltrials.gov, eudract.ema.europa.eu etc.) and analytics about thousands of clinical trials.
If you want to get an up-to-date and/or customized feasibility for Atopic Dermatitis or need an assessment about a different indication or TA, please contact us at firstname.lastname@example.org